Scarica l'app Stockscreener
123.89
0.44%
-0.55
Pre-mercato:
124.14
0.25
+0.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte Corporation (INCY) Stock Price Today: $123.89 - Pluang
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incyte Corp Lobbyists, 2025 - OpenSecrets
About 300 people in the U.S. have a disease that causes bone to form in soft tissues. FDA approves a treatment. - Stock Titan
Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP patients 12 and older - Mugglehead Investment Magazine
FDA Approves Atebrioz for Rare Bone Disorder, Boosting Incyte Co - gurufocus.com
Form 4 Incyte Corporation For: 25 September By Investing.com - Investing.com Canada
Form 4 Incyte Corporation For: 25 September - Investing.com India
Bay Area company readies for decision on drug to treat alarming 'stone man' syndrome - The Business Journals
Incyte (INCY) withheld shares from its strategy chief for taxes at a reported $126.93 per share. - Stock Titan
Incyte (INCY) Stock Could Be 34% Above Fair Value After EADV Data - Yahoo Finance
Incyte (INCY) Heads To EADV With New Skin Disease Trial Data - Yahoo Finance
Analysts Offer Insights on NA Companies: Incyte (INCY) and Coherent Corp (COHR) - The Globe and Mail
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - Barchart.com
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Incyte Corporation (INCY) latest stock news and headlines - Yahoo Finance UK
Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says - marketscreener.com
INCY Reiterated by RBC Capital -- Price Target Maintained at $10 - gurufocus.com
Incyte to present inflammation and autoimmunity data at EADV - Investing.com
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio - Business Wire
INCY Looks 18.6% Overvalued on GF Value™ as of September 2026 - GuruFocus
Incyte Expands Skin Diseases Treatment Partnership in Australia - marketscreener.com
Incyte stock heads into the open after a 1.8% pullback - AD HOC NEWS
Specialised Therapeutics expands Incyte partnership to Australia - Investing.com
More than 1 million patients have used this skin cream. Partners plan to bring it to Australia. - Stock Titan
Incyte stock gains institutional backing as Bank of America boosts position - AD HOC NEWS
Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target - Yahoo Finance
What Is Incyte Corporation (NASDAQ:INCY) Signaling Through Its Pipeline? - Kalkine Media
Incyte Stock Price Forecast. Should You Buy INCY? - StockInvest.us
Incyte stock gains as investors eye September FDA decision and pipeline catalysts - AD HOC NEWS
Incyte (NASDAQ:INCY) Combines Minervini Trend Template Strength With High-Growth Momentum - ChartMill
MIRM, INCY Stocks In Focus — Will A September 26 FDA Ruling Reward This Week’s Gains? - Stocktwits
Incyte stock heads into the open after a 2.5% gain - AD HOC NEWS
Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Incyte Insider Sold Shares Worth $2,797,629, According to a Recent SEC Filing - marketscreener.com
Incyte (INCY) R&D chief exercises options and sells 23,218 shares - Stock Titan
Incyte Corp. (INCY) Gains 1.85% to $123.99, Holding Near the Midpoint of Its Recent RangeLow Vol ETF - careplusvn.com
Incyte: Priced For Success, With No Margin Of Safety (NASDAQ:INCY) - Seeking Alpha
INCY Stock Gains 23% Year to Date: Buy, Sell or Hold? - Yahoo Finance
Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today - Benzinga
Cantor Fitzgerald reiterates Neutral on Incyte stock after conference - Investing.com
Profitable Biotech Incyte Stock Forms Handle Amid Strong Institutional Accumulation - Investor's Business Daily
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte at Cantor conference: pipeline advances, post-Jakafi plan - investing.com
Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - Investing.com India
Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup - ChartMill
Incyte Corp. (INCY) Peer Comparison – Compare with Others - Value Research
Incyte Corp. (INCY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Incyte (INCY) Institutional Ownership 2026 $INCY - MarketBeat
Incyte Corp. (INCY) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):